
Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.4%, driven by a pullback from Locus Cell of 12%. However, the industry is down 6.6% over the past year.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 18 Jun 2026 | NT$30.9b | NT$2.7b | -NT$747,832,000.00 | 20.9x | -41.4x | 11.7x |
| Sat, 16 May 2026 | NT$32.7b | NT$2.7b | -NT$747,832,000.00 | 21.5x | -43.7x | 12.3x |
| Mon, 13 Apr 2026 | NT$31.1b | NT$2.5b | -NT$767,980,000.00 | 21.8x | -40.5x | 12.4x |
| Wed, 11 Mar 2026 | NT$31.5b | NT$2.4b | -NT$692,870,000.00 | 19x | -45.5x | 13x |
| Fri, 06 Feb 2026 | NT$33.7b | NT$2.4b | -NT$689,929,000.00 | 23.9x | -48.9x | 13.9x |
| Sun, 04 Jan 2026 | NT$34.0b | NT$2.4b | -NT$689,929,000.00 | 25.8x | -49.3x | 14x |
| Tue, 02 Dec 2025 | NT$37.7b | NT$2.4b | -NT$670,921,000.00 | 19.4x | -56.2x | 15.4x |
| Thu, 30 Oct 2025 | NT$35.6b | NT$2.5b | -NT$870,437,000.00 | 18.5x | -40.9x | 14.5x |
| Sat, 27 Sep 2025 | NT$36.9b | NT$2.5b | -NT$870,437,000.00 | 19.8x | -42.4x | 15x |
| Mon, 25 Aug 2025 | NT$35.6b | NT$2.5b | -NT$819,216,000.00 | 20.6x | -43.5x | 14.5x |
| Wed, 23 Jul 2025 | NT$33.5b | NT$2.5b | -NT$600,003,000.00 | 21.9x | -55.8x | 13.6x |
| Fri, 20 Jun 2025 | NT$32.6b | NT$2.5b | -NT$600,003,000.00 | 23.2x | -54.3x | 13.2x |
| Sun, 18 May 2025 | NT$32.0b | NT$2.5b | -NT$604,301,000.00 | 23.4x | -52.9x | 13x |
| Tue, 15 Apr 2025 | NT$31.2b | NT$2.5b | -NT$540,128,000.00 | 23.7x | -57.8x | 12.7x |
| Thu, 13 Mar 2025 | NT$36.0b | NT$2.6b | -NT$851,729,000.00 | 24.7x | -42.3x | 14.1x |
| Sat, 08 Feb 2025 | NT$38.0b | NT$2.6b | -NT$854,432,000.00 | 23.9x | -44.4x | 14.8x |
| Mon, 06 Jan 2025 | NT$34.5b | NT$2.6b | -NT$854,432,000.00 | 22.8x | -40.4x | 13.5x |
| Wed, 04 Dec 2024 | NT$41.7b | NT$2.6b | -NT$854,432,000.00 | 24.4x | -48.8x | 16.3x |
| Fri, 01 Nov 2024 | NT$42.3b | NT$2.5b | -NT$712,402,000.00 | 24.2x | -59.3x | 16.8x |
| Sun, 29 Sep 2024 | NT$41.7b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -49.8x | 18.3x |
| Tue, 27 Aug 2024 | NT$40.9b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -48.8x | 18x |
| Thu, 25 Jul 2024 | NT$43.1b | NT$2.1b | -NT$797,765,000.00 | 33.3x | -54x | 20.2x |
| Sat, 22 Jun 2024 | NT$42.5b | NT$2.1b | -NT$797,765,000.00 | 34.3x | -53.2x | 19.9x |
| Mon, 20 May 2024 | NT$40.7b | NT$2.1b | -NT$797,765,000.00 | 32.1x | -51.1x | 19.1x |
| Wed, 17 Apr 2024 | NT$40.1b | NT$2.1b | -NT$923,759,000.00 | 29.9x | -43.4x | 19x |
| Fri, 15 Mar 2024 | NT$40.1b | NT$2.1b | -NT$611,249,000.00 | 32.2x | -65.6x | 19.5x |
| Sun, 11 Feb 2024 | NT$43.0b | NT$2.1b | -NT$610,218,000.00 | 32.4x | -70.4x | 20.7x |
| Tue, 09 Jan 2024 | NT$46.3b | NT$2.1b | -NT$610,218,000.00 | 34.1x | -75.9x | 22.3x |
| Thu, 07 Dec 2023 | NT$48.3b | NT$2.1b | -NT$610,218,000.00 | 33.6x | -79.2x | 23.3x |
| Sat, 04 Nov 2023 | NT$48.5b | NT$2.2b | -NT$497,769,000.00 | 31.8x | -97.4x | 21.8x |
| Mon, 02 Oct 2023 | NT$48.0b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -96.4x | 21.6x |
| Wed, 30 Aug 2023 | NT$43.4b | NT$2.2b | -NT$497,769,000.00 | 31x | -87.1x | 19.5x |
| Fri, 28 Jul 2023 | NT$47.8b | NT$2.5b | -NT$274,767,000.00 | 42.9x | -173.9x | 19.5x |
| Sun, 25 Jun 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 43.2x | -176.1x | 19.7x |
-176.1x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 6.12% | |
| Healthcare | 2.29% | |
| Life Sciences | -4.45% | |
| Clinical Research and Equipment | -4.45% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6848 RBC Bioscience | NT$20.30 | 3.6% +NT$10.0m | 24.1% | PE12.3x | |
| 6662 BioLASCO Taiwan | NT$30.35 | 1.2% +NT$9.0m | -11.3% | PE18.3x | |
| 6939 TFBS Bioscience | NT$20.20 | 1.0% +NT$7.0m | -12.9% | n/a |